Gland Pharma Reports 97% Increase in Q4 Profit, Strong Global Sales Growth
Gland Pharma Q4 PAT jumps 97% YoY to Rs 367 crore
Business Standard
Image: Business Standard
Gland Pharma's consolidated net profit surged by 96.62% to ₹366.7 crore in Q4 FY26, driven by a 22.31% rise in net sales to ₹1,742.80 crore. Growth was particularly strong in the USA and Europe, with revenues increasing 25.44% and 36% respectively, while the company continues to expand its product pipeline and launch new drugs.
- 01Profit before tax increased by 75.42% to ₹505.79 crore in Q4 FY26 compared to the previous year.
- 02The company launched five new molecules in the US during the quarter, bringing total launches for FY26 to 31 products.
- 03Gland Pharma's R&D expenses were ₹50.6 crore, representing 4% of base business revenue, focusing on complex product development.
- 04The board recommended a final dividend of ₹20 per equity share for FY26, pending approval at the AGM.
- 05Srinivas Sadu, Executive Chairman, highlighted a 38% adjusted EBITDA margin for the base business, attributing growth to new product launches and cost-efficiency initiatives.
Advertisement
In-Article Ad
Gland Pharma, based in Hyderabad, reported a remarkable 96.62% increase in consolidated net profit, reaching ₹366.7 crore for the fourth quarter of FY26, compared to ₹186.7 crore in the same quarter of the previous fiscal year. This growth was fueled by a 22.31% rise in net sales, totaling ₹1,742.80 crore. The company's revenue from the USA rose by 25.44% to ₹980.7 crore, while Europe saw a 36% increase in revenue to ₹381.4 crore. Despite a slight decline in sales in Canada, Australia, and New Zealand, domestic sales in India grew by 28% to ₹67 crore. Gland Pharma's profit before tax also saw a significant increase of 75.42%, amounting to ₹505.79 crore. The company launched five new molecules in the US during the quarter, contributing to a total of 31 launches for FY26. The board has proposed a final dividend of ₹20 per equity share, which will be paid within 30 days of the upcoming Annual General Meeting. Gland Pharma continues to strengthen its product pipeline and aims for sustained growth through new product launches and partnerships.
Advertisement
In-Article Ad
The significant profit increase and proposed dividend indicate strong financial health, which may enhance shareholder confidence and attract further investment.
Advertisement
In-Article Ad
Reader Poll
Do you think Gland Pharma will continue to grow in the coming quarters?
Connecting to poll...
Read the original article
Visit the source for the complete story.